Compare Abeona Therapeutics Inc (ABEO) vs Baker Hughes Co (BKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Baker Hughes Co — how do they compare? Abeona Therapeutics Inc trades at $6.76 (market cap $373.32M), while Baker Hughes Co trades at $57.19 (market cap $54.04B). The key difference: Baker Hughes Co is far larger — about 144.8× Abeona Therapeutics Inc's market cap, and Baker Hughes Co pays a 1.69% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | BKR | |
|---|---|---|
Market Cap | $373.32M | $54.04B |
Sector | Health | Energy |
52-Week High | $7.23 | $69.67 |
52-Week Low | $4.17 | $38.68 |
Enterprise Value | $228.22M | $55.44B |
Dividend Yield | — | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Baker Hughes (BKR) trades at $54.47, up 3.2% over the past 24 hours, with a bearish technical signal from moving averages but bullish oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q2 2026 results expected soon. Recent contract wins in Angola and Nigeria, along with expansion into geothermal energy, highlight growth initiatives. Financials show strong profitability with an 11.17% net income margin and improving cash flow trends, though revenue growth has moderated.
The outlook for BKR is positive, supported by analyst consensus with a $74.27 price target and 66.7% buy ratings. Key opportunities include energy transition projects and international contracts, while risks involve oil price volatility and integration challenges from the Chart Industries acquisition. The stock presents a value opportunity with a P/E of 17.01, trading below analyst targets amid operational strength.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
